share_log

Alnylam Pharmaceuticals | 8-K: Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals | 8-K: Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

阿里拉姆制药 | 8-K:Alnylam Pharmicals公布2024年第三季度财务业绩并重点介绍近期活动
美股SEC公告 ·  2024/10/31 20:16

Moomoo AI 已提取核心信息

Alnylam Pharmaceuticals has announced its financial results for the third quarter ended September 30, 2024. The announcement was made through a press release on October 31, 2024.The company has filed this information with the SEC via Form 8-K, with the financial results press release being furnished as Exhibit 99.1. The filing was authorized by Jeffrey V. Poulton, a senior executive of the company.
Alnylam Pharmaceuticals has announced its financial results for the third quarter ended September 30, 2024. The announcement was made through a press release on October 31, 2024.The company has filed this information with the SEC via Form 8-K, with the financial results press release being furnished as Exhibit 99.1. The filing was authorized by Jeffrey V. Poulton, a senior executive of the company.
阿里拉姆制药宣布截至2024年9月30日的第三季度财务业绩。该公告于2024年10月31日通过新闻稿发布。公司已经通过8-K表格向证券交易委员会(SEC)提交了这条信息,财务业绩的新闻稿作为99.1号附录提供。该文件由公司高级执行官Jeffrey V. Poulton授权。
阿里拉姆制药宣布截至2024年9月30日的第三季度财务业绩。该公告于2024年10月31日通过新闻稿发布。公司已经通过8-K表格向证券交易委员会(SEC)提交了这条信息,财务业绩的新闻稿作为99.1号附录提供。该文件由公司高级执行官Jeffrey V. Poulton授权。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息